Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;224(4):546-555.
doi: 10.1016/j.jamcollsurg.2016.12.015. Epub 2016 Dec 23.

Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study

Yanghee Woo  1 , Bryan Goldner  2 , Philip Ituarte  1 , Byrne Lee  1 , Laleh Melstrom  1 , Taeil Son  3 , Sung Hoon Noh  3 , Yuman Fong  1 , Woo Jin Hyung  4
Affiliations

Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study

Yanghee Woo et al. J Am Coll Surg. 2017 Apr.

Abstract

Background: Gastric adenocarcinoma is an aggressive disease with frequent lymph node (LN) metastases for which lymphadenectomy results in a survival benefit. In the US, the National Comprehensive Cancer Network guidelines recommend D2 lymphadenectomy or a minimum of 15 LNs retrieved. However, retrieval of only 15 LNs is considered by most international guidelines as inadequate. We sought to evaluate the survival benefits associated with a more complete lymphadenectomy.

Study design: An international database was constructed by combining gastric cancer cases from the Surveillance, Epidemiology, and End Results program database (n = 13,932) and the Yonsei University Gastric Cancer database (n = 11,358) (total n = 25,289). Kaplan-Meier survival analysis was performed along with Joinpoint analysis to obtain the optimal number of LNs to retrieve based on survival. Prognostic significance of number of nodes retrieved was then confirmed with univariate and multivariate analyses.

Results: Analysis for both mean and median survival yielded 29 LNs removed as the Joinpoint. This was confirmed with multivariate analysis, where 15 retrieved LNs cutoff fell out of the model and 29 retrieved LNs remained intact, with a hazard ratio of 0.799 (95% CI 0.759 to 0.842; p < 0.001). Stage-stratified Kaplan-Meier analysis for a cutoff point of 29 LNs also demonstrated a statistically significant improvement in survival.

Conclusions: Joinpoint analysis has allowed for the creation of a model demonstrating the point at which additional dissection would not provide additional benefit. This large international dataset analysis demonstrates that the maximal survival advantage is seen by performing a lymphadenectomy with a minimum of 29 LNs retrieved.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve demonstrating stage specific survival.
Figure 2
Figure 2
Joinpoint analysis demonstrating a Joinpoint at 29 lymph nodes removed for (A) mean survival, and (B) median survival.
Figure 3
Figure 3
Kaplan-Meier analysis comparing survival for those with <29 lymph nodes removed and those with > 29 lymph nodes removed for Stage 1a–3c. All comparisons of <29 nodes retrieved and >29 nodes retrieved, p<001.
Figure 4
Figure 4
Stage migration analysis. Data demonstrates stage migration for patients with inadequate lymphadenectomy (<29 nodes retrieved) to the next worse stage.
See this image and copyright information in PMC

Comment in

  • Discussion.
    [No authors listed] [No authors listed] J Am Coll Surg. 2017 Apr;224(4):555-556. doi: 10.1016/j.jamcollsurg.2017.01.026. J Am Coll Surg. 2017. PMID: 28343498 No abstract available.

References

    1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11–20. - PubMed
    1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725–30. - PubMed
    1. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315–21. - PubMed
    1. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810–20. - PubMed
    1. Choi YY, An JY, Katai H, et al. A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. PLoS One. 2016;11(3):e0149555. - PMC - PubMed

MeSH terms